MarketPulse

artificially inflated prices

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Gossamer Bio Hit With Class Action Over Failed Phase 3 Trial Disclosures

Class action lawsuit filed against Gossamer Bio for allegedly concealing design flaws in Phase 3 PROSERA study, claiming investors purchased stock at artificially inflated prices.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Gossamer Bio Faces Class Action Over Alleged Misstatements on Phase 3 Trial Results

Class action lawsuit filed against Gossamer Bio alleging material misstatements regarding Phase 3 PROSERA study results and hidden design flaws at Latin American test sites.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Gossamer Bio Faces Class Action Over Allegedly Misleading Phase 3 Trial Data

Class action lawsuit filed against Gossamer Bio for alleged false statements regarding Phase 3 PROSERA study results and concealed trial design issues at Latin American sites.
GOSSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Varonis Systems Faces Class Action Over SaaS Conversion Disclosures

Varonis Systems faces class action lawsuit alleging false statements about SaaS conversion capabilities inflated stock prices. Investors who bought shares between February-October 2025 may qualify.
VRNSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Varonis Systems Over SaaS Conversion Disclosures

Varonis Systems faces class action lawsuit alleging false statements about SaaS conversion capabilities artificially inflated stock prices, harming shareholders during February-October 2025.
VRNSsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Ultragenyx Investors Face April Deadline in Securities Fraud Class Action

Rosen Law Firm sues Ultragenyx for securities fraud, alleging executives misrepresented drug efficacy. Investors who bought stock August 2023-December 2025 can claim damages by April 6, 2026 deadline.
RAREsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

F5 Faces Class Action Over Alleged Misstatements on Security and Product Breaches

F5 faces class action lawsuit alleging it misrepresented security capabilities and failed to disclose a major product breach affecting investors between October 2024-2025.
FFIVsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Varonis Systems Faces Class Action Lawsuit Over SaaS Conversion Disclosures

Varonis Systems faces class action lawsuit alleging false statements about SaaS conversion capabilities, causing artificially inflated stock prices between February-October 2025.
VRNSsecurities fraudclass action lawsuit